Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation Collaboration in Oncology
ORION CORP NEW UNSP/ADR (ORINY)
NASDAQ:AMEX Investor Relations:
orion.fi/en/orion-group/investors/investor-relations
Company Research
Source: GlobeNewswire
ORION CORPORATION PRESS RELEASE 25 SEPTEMBER 2024 at 15.00 EEST Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation Collaboration in Oncology Orion Corporation and Aitia, an AI-enabled biotechnology company and the leader in the development and application of Causal AI and "Digital Twins" to discover and develop new drugs, announced today that the companies have entered into agreement to create new Gemini Digital Twins to help in the fight against cancer. Cancer is a critical global health issue, affecting millions of people worldwide and imposing a significant burden on healthcare systems. In 2022 alone, nearly 20 million new cancer cases were diagnosed, with 10 million lives lost to the disease1. The global cancer burden is projected to rise significantly, with new cases expected to reach 35 million annually by 2050 if current trends continue, driven by population aging and growth. This growing challenge underscores the urgent need for inn
Show less
Read more
Impact Snapshot
Event Time:
ORINY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ORINY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ORINY alerts
High impacting ORION CORP NEW UNSP/ADR news events
Weekly update
A roundup of the hottest topics
ORINY
News
- Bayer Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Indication for NUBEQA® (darolutamide) in Metastatic Hormone-Sensitive Prostate Cancer [Yahoo! Finance]Yahoo! Finance
- Orion’s collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has become the first ever Orion-originated blockbusterGlobeNewswire
- 213,285 Orion Corporation A shares converted into B shares [Yahoo! Finance]Yahoo! Finance
- Inside information: Orion upgrades full-year outlook for 2024 [Yahoo! Finance]Yahoo! Finance
- 3 Reasons Why Growth Investors Shouldn't Overlook Orion OYJ (ORINY) [Yahoo! Finance]Yahoo! Finance